Affiliation:
1. The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA, 90502, United States
2. 3Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, 91125, United States
Abstract
Abstract
Background: p97/VCP, a hexametric member of the AAA-ATPase super family, has been associated with a wide range of cellular protein pathways such as proteasomal degradation, unfolding of polyubiquitinated proteins, and autophagosome maturation. Autosomal dominant p97/VCP mutations cause a rare hereditary multisystem disorder called IBMPFD/ALS (Inclusion Body Myopathy with Paget’s Disease and Frontotemporal Dementia/Amyotrophic Lateral Sclerosis), characterized by progressive weakness and subsequent atrophy of skeletal muscles and impacting bones and brains, such as Parkinson's disease, Lewy body disease, Huntington's disease, and amyotrophic lateral ALS. Among all disease-causing mutations, Arginine 155 to Histidine (R155H/+) was reported to be the most common one, affecting over 50% of IBMPFD patients, resulting in disabling muscle weakness, which might eventually be life-threatening due to cardiac and respiratory muscle involvement.
Methods:Induced pluripotent stem cells (iPSCs) offer an unlimited resource of cells to study pathology’s underlying molecular mechanism, perform drug screening, and investigate regeneration. Using R155H/+ patients' fibroblasts, we generated IPS cells and corrected the mutation (Histidine to Arginine, H155R) to generate isogenic control cells before differentiated them into myotubes. Further proteomic analysis allowed us to identify a series of differentially expressed proteins associated with the R155H mutation.
Results: Our results showed that R155H/+ cells were associated with dysregulated expression of several proteins involved in skeletal muscle function, cytoskeleton organization, cell signaling, intracellular organelles organization and function, cell junction, and cell adhesion.
Conclusions: Our findings provide molecular evidence of dysfunctional protein expression in R155H/+ myotubes and provide new therapeutic targets for the treatment of IBMPFD/ALS.
Publisher
Research Square Platform LLC